Doxorubicin ( DrugBank: Doxorubicin )


5 diseases
IDDisease name (Link within this page)Number of trials
26HTLV-1-associated myelopathy3
28Systemic amyloidosis1
34Neurofibromatosis1
65Primary immunodeficiency1
331Idiopathic multicentric castleman disease3

26. HTLV-1-associated myelopathy


Clinical trials : 29Drugs : 47 - (DrugBank : 29) / Drug target genes : 34 - Drug target pathways : 119 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

28. Systemic amyloidosis


Clinical trials : 267Drugs : 241 - (DrugBank : 77) / Drug target genes : 68 - Drug target pathways : 180 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

34. Neurofibromatosis


Clinical trials : 133Drugs : 186 - (DrugBank : 67) / Drug target genes : 79 - Drug target pathways : 190 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

65. Primary immunodeficiency


Clinical trials : 500Drugs : 614 - (DrugBank : 119) / Drug target genes : 92 - Drug target pathways : 217 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

331. Idiopathic multicentric castleman disease


Clinical trials : 33Drugs : 41 - (DrugBank : 21) / Drug target genes : 22 - Drug target pathways : 123 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries